Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522378 · ClinicalTrials.gov registry record · Phase 1
Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01522378: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT01522378 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01522378, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Subjects were recruited if their healthcare provider decided that they needed treatment with a special Internal Cardiac Defibrillator (ICD) called a biventricular ICD. The investigators did this study to see if part of the nerve organ, called the sympathetic nervous system, may be responsible for the improvement seen in patients that receive biventricular pacing. The investigators had three ways to measure sympathetic nervous activity: 1) by using a special blood sample, 2) by monitoring heart rhythm, and 3) by performing a special heart scan.
Interventions
- DRUG 123 iodine metaiodobenzylguanidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-02 |
| Est. Completion | 2016-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01522378
The ClinicalTrials.gov registry entry for NCT01522378 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 123 iodine metaiodobenzylguanidine is the first listed.
NCT01522378 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01522378 about?
NCT01522378 is a clinical study titled "Cardiac Resynchronization and Iodine Meta-Iodobenzylguanidine (MIBG) Imaging". Subjects were recruited if their healthcare provider decided that they needed treatment with a special Internal Cardiac Defibrillator (ICD) called a biventricular ICD. The investigators did this study to see if part of the nerve organ, called the sympathetic nervous system, may be responsible for th...
What is the current status of trial NCT01522378?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-02. Estimated completion is 2016-02.
What interventions are being tested in trial NCT01522378?
The interventions under investigation include: 123 iodine metaiodobenzylguanidine (DRUG).
Who is sponsoring clinical trial NCT01522378?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.